ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC
Lung Cancer. 2025 Aug:206:108635.
doi: 10.1016/j.lungcan.2025.108635.
Epub 2025 Jun 23.
1 Oncology and Haematology Department, Inselspital - Universitatsklinik fur Medizinische Onkologie, Bern, Switzerland; Swiss Group for Clinical Cancer Research (SAKK), Switzerland.
3 Department of Thoracic and Vascular Surgery, UZA - University Hospital Antwerp, Edegem, Belgium.
4 Swiss Group for Clinical Cancer Research (SAKK), Switzerland; Universitätsspital, Basel, Switzerland.
5 Swiss Group for Clinical Cancer Research (SAKK), Switzerland; Kantonsspital Winterthur, Switzerland.
6 Medical Oncology Department, Peter MacCallum Cancer Center, Melbourne, Australia; Thoracic Oncology Group of Australasia (TOGA), Australia.
7 Swiss Group for Clinical Cancer Research (SAKK), Switzerland; St. Gallen, Australia.
8 Chemotherapy Department, North Estonia Medical Centre Foundation (SA Pohja-Eesti Regionaalhaigla), Tallinn, Estonia.
9 Oncology Department, IRCCS Istituto Nazionale Tumori Regina Elena (IRE), Rome, Italy.
10 Medical Oncology Department, Centre Léon Bérard, Lyon, France.
11 Department of Medicine, The Royal Marsden Hospital - NHS Foundation Trust, London, United Kingdom.
12 Thoracic Surgery Department, Medical University Vienna, Vienna, Austria.
13 Oncology Department, Trinity St. Jame's Cancer Institute, Dublin, Ireland.
14 University Medical Center Utrecht, the Netherlands.
15 Coordinating Center, ETOP IBCSG Partners Foundation, Bern, Switzerland.
16 Histopathology, St James's Hospital, Dublin, Ireland.
17 ETOP Statistical Office, FSF-H - Frontier Science Foundation Hellas, Athens, Greece; Public Health Division, Department of Nursing, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece.